Research into heart drugs takes back seat to faster oncology studies

09/3/2013 | Reuters

Research into new heart drugs has taken a back seat to development of other disease treatments, especially cancer, according to cardiologists at the European Society of Cardiology annual meeting. Part of the problem is that researchers can use genetics to target oncology drugs, but heart studies require longer and more expensive trials. AstraZeneca's head of global medicines development, Briggs Morrison, said biotech companies that focus on oncology have a faster path to approval with small patient populations, meaning investors can see a return.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ